Xceed Molecular, formerly Metrigenix, said last week it has appointed David Deems as president. He replaces Michael Cohen, who will become non-executive chairman of the board.
Deems was previously vice president of development and operations at Predicant Biosciences, where he had also been vice president of development and operations. He was also vice president of product development at Exact Sciences, CEO of Union Biometrica, and was an executive at BD Biosciences.